JP2009256392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009256392A5 JP2009256392A5 JP2009187809A JP2009187809A JP2009256392A5 JP 2009256392 A5 JP2009256392 A5 JP 2009256392A5 JP 2009187809 A JP2009187809 A JP 2009187809A JP 2009187809 A JP2009187809 A JP 2009187809A JP 2009256392 A5 JP2009256392 A5 JP 2009256392A5
- Authority
- JP
- Japan
- Prior art keywords
- riera
- dunaliella
- donna
- genus
- crude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000195634 Dunaliella Species 0.000 claims description 60
- 239000000843 powder Substances 0.000 claims description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
- 229940125753 fibrate Drugs 0.000 claims description 28
- 201000001320 Atherosclerosis Diseases 0.000 claims description 24
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 241000195493 Cryptophyta Species 0.000 claims description 17
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 14
- 102000006255 nuclear receptors Human genes 0.000 claims description 14
- 108020004017 nuclear receptors Proteins 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 241000195633 Dunaliella salina Species 0.000 claims description 10
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 10
- 229960004586 rosiglitazone Drugs 0.000 claims description 9
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 claims description 8
- 102000023984 PPAR alpha Human genes 0.000 claims description 8
- 108010016731 PPAR gamma Proteins 0.000 claims description 8
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 229960002174 ciprofibrate Drugs 0.000 claims description 8
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 claims description 8
- 210000003291 sinus of valsalva Anatomy 0.000 claims description 7
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960002297 fenofibrate Drugs 0.000 claims description 6
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 6
- 229960000516 bezafibrate Drugs 0.000 claims description 5
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 4
- 229960001214 clofibrate Drugs 0.000 claims description 4
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical group CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 4
- 229960003627 gemfibrozil Drugs 0.000 claims description 4
- AFSHNJLKCYAWRX-UHFFFAOYSA-N 4-[(5-chloronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(Cl)=CC=CC2=CC=1CC1=NS(=O)ON1 AFSHNJLKCYAWRX-UHFFFAOYSA-N 0.000 claims description 3
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims description 3
- YVQKIDLSVHRBGZ-UHFFFAOYSA-N 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1C(O)COC(C=C1)=CC=C1CC1SC(=O)NC1=O YVQKIDLSVHRBGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 3
- 229940062310 avandia Drugs 0.000 claims description 3
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 claims description 3
- 229950006689 darglitazone Drugs 0.000 claims description 3
- 229950002375 englitazone Drugs 0.000 claims description 3
- 229960005095 pioglitazone Drugs 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical group [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 102000000536 PPAR gamma Human genes 0.000 claims 4
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 2
- 229950009226 ciglitazone Drugs 0.000 claims 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 27
- 108010010234 HDL Lipoproteins Proteins 0.000 description 20
- 102000015779 HDL Lipoproteins Human genes 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 18
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 18
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 17
- 235000013734 beta-carotene Nutrition 0.000 description 17
- 239000011648 beta-carotene Substances 0.000 description 17
- 102000034527 Retinoid X Receptors Human genes 0.000 description 16
- 108010038912 Retinoid X Receptors Proteins 0.000 description 16
- 229960002747 betacarotene Drugs 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 229960001445 alitretinoin Drugs 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 9
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 230000036523 atherogenesis Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 229930002330 retinoic acid Natural products 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 102100038495 Bile acid receptor Human genes 0.000 description 6
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 108090000865 liver X receptors Proteins 0.000 description 5
- 102000004311 liver X receptors Human genes 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
- 235000021068 Western diet Nutrition 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001906 cholesterol absorption Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000004141 reverse cholesterol transport Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- OENHQHLEOONYIE-BVZAMQQESA-N 9-cis-beta-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-BVZAMQQESA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 3
- 229940121908 Retinoid X receptor agonist Drugs 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- -1 retinoid compounds Chemical class 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 2
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 2
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 2
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 101000603962 Homo sapiens Oxysterols receptor LXR-alpha Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100038476 Oxysterols receptor LXR-alpha Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- 230000002034 xenobiotic effect Effects 0.000 description 2
- SSCSSDNTQJGTJT-UHFFFAOYSA-N (3,6-dihydroxy-1-methyl-2,3-dihydroindol-5-yl)iminourea Chemical compound CN1CC(O)C2=CC(N=NC(N)=O)=C(O)C=C12 SSCSSDNTQJGTJT-UHFFFAOYSA-N 0.000 description 1
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 108010005254 Activating Transcription Factors Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 101000603958 Homo sapiens Oxysterols receptor LXR-beta Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101150027485 NR1H4 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100038477 Oxysterols receptor LXR-beta Human genes 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004903 negative regulation of intestinal cholesterol absorption Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/668,601 US7264813B2 (en) | 2003-09-24 | 2003-09-24 | Therapeutic uses of Dunaliella powder |
| US10/668601 | 2003-09-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004212054A Division JP5020463B2 (ja) | 2003-09-24 | 2004-07-20 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013126599A Division JP2013177457A (ja) | 2003-09-24 | 2013-06-17 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009256392A JP2009256392A (ja) | 2009-11-05 |
| JP2009256392A5 true JP2009256392A5 (enExample) | 2012-01-19 |
| JP5356946B2 JP5356946B2 (ja) | 2013-12-04 |
Family
ID=34313520
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004212054A Expired - Fee Related JP5020463B2 (ja) | 2003-09-24 | 2004-07-20 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
| JP2009187809A Expired - Lifetime JP5356946B2 (ja) | 2003-09-24 | 2009-08-13 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
| JP2013126599A Withdrawn JP2013177457A (ja) | 2003-09-24 | 2013-06-17 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
| JP2016104166A Expired - Fee Related JP6321074B2 (ja) | 2003-09-24 | 2016-05-25 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
| JP2017235555A Expired - Lifetime JP6490782B2 (ja) | 2003-09-24 | 2017-12-07 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004212054A Expired - Fee Related JP5020463B2 (ja) | 2003-09-24 | 2004-07-20 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013126599A Withdrawn JP2013177457A (ja) | 2003-09-24 | 2013-06-17 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
| JP2016104166A Expired - Fee Related JP6321074B2 (ja) | 2003-09-24 | 2016-05-25 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
| JP2017235555A Expired - Lifetime JP6490782B2 (ja) | 2003-09-24 | 2017-12-07 | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US7264813B2 (enExample) |
| EP (2) | EP1522310B1 (enExample) |
| JP (5) | JP5020463B2 (enExample) |
| AT (1) | ATE548046T1 (enExample) |
| IL (1) | IL162987A (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007210917A (ja) * | 2006-02-08 | 2007-08-23 | Kochi Univ | 脂肪細胞縮小化剤、医薬品及び飲食品 |
| WO2007109824A1 (en) * | 2006-03-24 | 2007-10-04 | Ian Simon Tracton | Stable packaged dosage form and process therefor |
| JP2008222555A (ja) * | 2007-03-08 | 2008-09-25 | Nagasakiken Koritsu Daigaku Hojin | アディポネクチン受容体発現増加剤 |
| WO2009105048A2 (fr) * | 2008-02-19 | 2009-08-27 | Rached Smida | Nouvelles applications du hdl reconstitué |
| EP2296682B8 (en) | 2008-04-29 | 2018-07-04 | Nikken Sohonsha Corporation | Methods of treating ophthalmic disorders |
| US20100303989A1 (en) | 2008-10-14 | 2010-12-02 | Solazyme, Inc. | Microalgal Flour |
| JP5733592B2 (ja) * | 2008-10-20 | 2015-06-10 | 株式会社日健総本社 | 脂質異常治療薬の副作用防止物質 |
| WO2010102056A1 (en) * | 2009-03-03 | 2010-09-10 | Solazyme, Inc. | Methods of treating impaired glucose metabolism via administration of algal biomass |
| US9180152B2 (en) | 2009-12-10 | 2015-11-10 | Nikken Sohonsha Corporation | Method for treating psoriasis |
| JP5736394B2 (ja) | 2010-03-02 | 2015-06-17 | ヴィシェイ−シリコニックス | 半導体装置の構造及びその製造方法 |
| US10098371B2 (en) | 2013-01-28 | 2018-10-16 | Solazyme Roquette Nutritionals, LLC | Microalgal flour |
| FR3009619B1 (fr) | 2013-08-07 | 2017-12-29 | Roquette Freres | Compositions de biomasse de microalgues riches en proteines de qualite sensorielle optimisee |
| GB201718822D0 (en) | 2017-11-14 | 2017-12-27 | Univ Greenwich | Production of dunaliella |
| JP6947665B2 (ja) * | 2018-03-13 | 2021-10-13 | アイカ工業株式会社 | 光硬化性粘着樹脂組成物 |
| US20220175860A1 (en) * | 2019-04-01 | 2022-06-09 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Dunaliella alga preparation for prevention and/or treatment of a neurodegenerative disease, a disorder associated with protein misfolding and cognitive decline |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4199895A (en) | 1977-05-25 | 1980-04-29 | Yeda Research And Development Co. Ltd. | Production of glycerol, carotenes and algae meal |
| USPP4511P (en) | 1978-06-26 | 1980-03-18 | Yeda Research & Development Co. Ltd. | Alga strain |
| DE3729209A1 (de) | 1987-09-01 | 1989-03-09 | Boehringer Mannheim Gmbh | Verwendung von bezafibrat zur behandlung von diabetes |
| IL87260A (en) * | 1988-02-25 | 1991-12-15 | Tanaka Yoshio | Encapsulated food containing dunaliella algae and its production |
| US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| US5219888A (en) | 1992-03-31 | 1993-06-15 | American Cyanamid Company | Use of retinoids for the treatment of coronary artery disease |
| WO1993024454A1 (en) | 1992-06-04 | 1993-12-09 | Betatene Limited | High cis beta-carotene composition |
| US6262109B1 (en) * | 1995-12-22 | 2001-07-17 | Henkel Corporation | Methods of preventing and/or treating high serum levels of cholesterol and/or lipids |
| WO1997010819A1 (en) | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Treating niddm with rxr agonists |
| EP0788353A1 (en) * | 1995-09-18 | 1997-08-13 | Ligand Pharmaceuticals, Inc. | Ppar gamma antagonists for treating obesity |
| IL119224A (en) | 1996-09-09 | 2002-11-10 | Hadasit Med Res Service | Medicament for protection from effects of irradiation |
| JP3037628B2 (ja) * | 1997-03-06 | 2000-04-24 | マイクロアルジェコーポレーション株式会社 | 健康補助食品用軟カプセルの製法 |
| GB9712866D0 (en) * | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
| US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| EP1144997A3 (en) | 1998-03-30 | 2002-08-28 | The Regents of the University of California | Methods and compounds for modulating nuclear receptor activity |
| DE69929996T2 (de) | 1998-06-30 | 2006-11-16 | Takeda Pharmaceutical Co. Ltd. | Pharmazeutisches mittel zur behandlung von diabetes |
| JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| IL126447A (en) * | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
| AU776664B2 (en) | 1998-12-23 | 2004-09-16 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| US6914073B2 (en) * | 1999-03-18 | 2005-07-05 | Bristol Myers Squibb Company | Vitamin formulation for cardiovascular health |
| FR2795961B1 (fr) | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation |
| US6593493B1 (en) | 1999-09-14 | 2003-07-15 | Ligand Pharmaceuticals, Inc. | RXR modulators with improved pharmacologic profile |
| US6680387B2 (en) * | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| GB0019226D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
| AU2002333655A1 (en) | 2001-09-25 | 2003-04-07 | Smithkline Beecham Corporation | Bicyclic heterocycles as rxr ligands |
| IN189624B (enExample) * | 2001-10-23 | 2003-03-29 | Ajanta Pharma Ltd | |
| JP3978582B2 (ja) * | 2001-12-19 | 2007-09-19 | 株式会社日健総本社 | カロチノイドの製造方法 |
| US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
-
2003
- 2003-09-24 US US10/668,601 patent/US7264813B2/en not_active Expired - Lifetime
-
2004
- 2004-07-13 IL IL162987A patent/IL162987A/en active IP Right Grant
- 2004-07-20 JP JP2004212054A patent/JP5020463B2/ja not_active Expired - Fee Related
- 2004-08-12 EP EP04019206A patent/EP1522310B1/en not_active Expired - Lifetime
- 2004-08-12 EP EP10010882A patent/EP2269620A1/en not_active Withdrawn
- 2004-08-12 AT AT04019206T patent/ATE548046T1/de active
-
2007
- 2007-07-10 US US11/822,786 patent/US7763255B2/en not_active Expired - Lifetime
-
2009
- 2009-08-13 JP JP2009187809A patent/JP5356946B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-11 US US12/777,757 patent/US8343549B2/en not_active Expired - Fee Related
-
2013
- 2013-06-17 JP JP2013126599A patent/JP2013177457A/ja not_active Withdrawn
-
2016
- 2016-05-25 JP JP2016104166A patent/JP6321074B2/ja not_active Expired - Fee Related
-
2017
- 2017-12-07 JP JP2017235555A patent/JP6490782B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5356946B2 (ja) | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 | |
| JP2009256392A5 (enExample) | ||
| CN1993119B (zh) | 含他汀类药物和ω-3脂肪酸的组合物 | |
| JP2755559B2 (ja) | 前脂肪細胞の分化を刺激する組成物と方法、およびこれに関連する治療処置方法 | |
| AU2001286576B2 (en) | Composition and method for treatment of hypertriglyceridemia | |
| EA011637B1 (ru) | Лечение с использованием омега-3 жирных кислот и агониста и/или антагониста ppar и их комбинированный продукт | |
| AU2001286576A1 (en) | Composition and method for treatment of hypertriglyceridemia | |
| JP2008521863A (ja) | Ｈｉｖ感染患者における抗レトロウイルス治療がひき起こす高コレステロール血症の治療のためのオメガ−３脂肪酸の利用 | |
| JP5810166B2 (ja) | 糖尿病性心血管合併症の予防・治療剤 | |
| AU2015279905A1 (en) | Treatment of severe hypertriglyceridemia | |
| US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
| Black | Atorvastatin: a step ahead for HMG-CoA reductase inhibitors | |
| HK1071845B (en) | Therapeutic uses of dunaliella powder | |
| JP2020503388A (ja) | 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物 | |
| WO1993009773A1 (fr) | Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee |